Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects

Fig. 3

Median plasma concentration-time profile of MAD of PF-06650833 IR and MR formulations at steady state on day 14. Time post-dose refers to the first morning dose on day 14. Day 14 data for cohort 5 (IR 1000 mg QID) were not available due to premature discontinuation of this cohort on day 9. Summary statistics were calculated by setting concentration values BLQ to 0. The LLOQ was 0.0500 ng/mL, except four pre-dose samples with LLOQ of 0.100 ng/mL. All doses were administered orally under fed conditions (standard meal). BID twice daily; BLQ below lower limit of quantification; IR immediate-release; LLOQ lower limit of quantification; MAD multiple ascending doses; MR modified-release; QD once daily; QID four times per day; TID three times per day

Back to article page